跳至主要内容
临床试验/NCT03478306
NCT03478306已完成3 期

Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm

Glostrup University Hospital, Copenhagen1 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2018年3月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
31
试验地点
1
主要终点
Progression of diabetic retinopathy, oscillary potential

研究概览

简要总结

This study evaluates the effect of melatonin 4 mg on circadian rhythm and visual function of patients with diabetes mellitus. Half of the patients will receive melatonin (arm-1) and the other half will receive placebo (arm-2), both groups in 3 weeks. After a week of washout, the patients will cross over to the other treatment arm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Melatonin and placebo tablets are identicle in terms of taste, colour, tablet-size etc. The tablets are packed and masked by external manufacturer.

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diabetic patients
  • Age range 40-75 years
  • Participant should be legally competent

排除标准

  • Other known eye disease.
  • Eye disease manifestation during ocular examination.
  • Competing neurologic and systemic conditions affecting retina.
  • Use of any drugs influencing pupillary light reflex and sleep pattern.
  • Refractive error with need of > 6 diopter lenses.
  • Pregnancy
  • Alcohol consumption during the trial
  • Lack of cooperation
  • Allergy to melatonin and/or preservatives in melatonin and placebo
  • Reduced hepatic function
  • Fluvoxamin intake due to drug interaction
  • Consumption of Alpha-1 and beta-1 adnergic antagoists.
  • Alcohol consumption during treatment

研究组 & 干预措施

Arm 1

Active Comparator

Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.

干预措施: Melatonin 4 mg Tablet (Drug)

Arm 2

Placebo Comparator

Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.

干预措施: Melatonin 4 mg Tablet (Drug)

结局指标

主要结局

Progression of diabetic retinopathy, oscillary potential

时间窗: 3 weeks

Progression of diabetic retinopati measured with electroretinography

次要结局

  • Post-illumination pupillary light response(3 weeks)
  • Circadian photoentrainment(3 weeks)
  • Retinal structure(3 weeks)

研究者

发起方
Glostrup University Hospital, Copenhagen
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shakoor Ba-Ali

Principal Investigator, Medical Doctor

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验